Efficacy and Safety of Tocilizumab for Polyarticular‐Course Juvenile Idiopathic Arthritis in the Open‐Label Two‐Year Extension of a Phase III Trial

OBJECTIVE: To report the 2‐year efficacy and safety of tocilizumab (TCZ) in patients with polyarticular‐course juvenile idiopathic arthritis (JIA). METHODS: Patients ages 2–17 years with active polyarticular‐course JIA, in whom treatment with methotrexate was unsuccessful, received 16 weeks of open‐...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Arthritis Rheumatol
Egile Nagusiak: Brunner, Hermine I., Ruperto, Nicolino, Zuber, Zbigniew, Cuttica, Rubén, Keltsev, Vladimir, Xavier, Ricardo M., Burgos‐Vargas, Ruben, Penades, Inmaculada Calvo, Silverman, Earl D., Espada, Graciela, Zavaler, Manuel Ferrandiz, Kimura, Yukiko, Duarte, Carolina, Job‐Deslandre, Chantal, Joos, Rik, Douglass, Wendy, Wimalasundera, Sunethra, Bharucha, Kamal N., Wells, Chris, Lovell, Daniel J., Martini, Alberto, de Benedetti, Fabrizio
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2021
Gaiak:
Pediatric Rheumatology
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7986602/
https://ncbi.nlm.nih.gov/pubmed/32951358
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.41528
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak